UNASSIGNED: We aimed to record all new @entity1 who presented to departments of oral surgery, oral medicine, and oral and maxillofacial surgery, and to dental hospitals in the UK, with @entity2530 of the jaws including bisphosphonate-related @entity39 (BRONJ) over a 2-year period (1 June 2009-31 May 2011). They were eligible irrespective of age, cause, or coexisting conditions. Data on incidence, clinical characteristics, risk factors, and coexisting conditions were collected. A total of 383 cases were registered: 369 were described as BRONJ, 5 as @entity2530 , and 9 were unknown. Bisphosphonates had been given orally in 207 (56%), intravenously in 125 (34%), both orally and intravenously in 27 (7%), and was unknown in 9 (2%); one had been given denosumab. The main risk factor was dental extraction, and the mandible was commonly affected. The median duration of administration until onset of BRONJ was 3 years in those treated intravenously and 4 years in those treated orally. Levels of engagement with the study varied between regions, and extrapolation from the 2 most involved (Merseyside and Northern Ireland) found around 8.2-12.8 cases/million/year, which is 508-793 @entity1 /year across the UK. To our knowledge this is one of the first studies to estimate national rates of BRONJ. It confirms that the risk and incidence are low. With changes in trends for antiresorptive bone medication, and increasing numbers of elderly @entity1 , it would be useful to repeat the registration in the future.

United Kingdom nationwide study of XXXX of the jaws including bisphosphonate-related @entity39 .

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity2530 :: ('MESH:D010020', 'Disease') :: ['avascular necrosis']
@entity2530 :: (MESH:D010020,Disease) :: ['avascular necrosis']
